ОПРЕДЕЛЕНИЕ АКТИВНОСТИ РЕНИНА ПЛАЗМЫ КАК СТРАТЕГИЯ ВЫБОРА И ИЗМЕНЕНИЯ АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ
https://doi.org/10.18705/1607-419X-2013-19-5-380-388
Аннотация
В последние годы вновь возник интерес к определению активности ренина плазмы (АРП) как к возможности влияния на тактику выбора и изменения антигипертензивной терапии. Исследование АРП для определения тактики лечения основывается на понимании взаимодействия между ренин-ангиотензин-альдостероновой системой (РААС) и механизмом поддержания водного баланса в организме посредством всасывания натрия почками и задержки жидкости.Определение АРП может ответить на вопрос, какая из систем — первичный участник в повышении артериального давления (АД). Если артериальная гипертензия (АГ) связана с задержкой натрия в организме, то уровень АРП составляет < 0,65 нг/мл/ч. Эти пациенты относятся к низкорениновой объем-зависимой АГ. Если АРП составляет 0,65 нг/мл/ч и более, то развитие АГ связано с чрезмерным высвобождением ренина и активацией РААС. Двойной механизм регуляции АД лежит в основе действия антигипертензивных препаратов, основанного на натрийуретическом эффекте (анти-«объем» препараты) и на противорениновом действии (анти-«ренин» препараты). Определение АРП у пациентов с АГ может помочь как в выборе, так и в добавлении или прекращении приема гипотензивных препаратов с целью улучшения контроля АД при одновременном уменьшении количества применяемых препаратов и их стоимости.
Об авторах
Ю. В. Котовская
Российский университет дружбы народов, Москва
Россия
Россия
Доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней РУДН.
Контактная информация: Городская клиническая больница № 64, кафедра пропедевтики внутренних болезней Российского университета дружбы народов, ул. Вавилова, д. 61, Москва, Россия, 117292. E-mail: kotovskaya@bk.ru (Котовская Юлия Викторовна).
О. А. Кравцова
Российский университет дружбы народов, Москва
Россия
Аспирант кафедры пропедевтики внутренних болезней РУДН
Россия
Аспирант кафедры пропедевтики внутренних болезней РУДН
Е. А. Павлова
Российский университет дружбы народов, Москва
Россия
Ассистент кафедры пропедевтики внутренних болезней РУДН
Россия
Ассистент кафедры пропедевтики внутренних болезней РУДН
Список литературы
1. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008 //J. Am. Med. Assoc. — 2010. — Vol. 303, № 20. — P. 2043–2050.
2. Hajjar I., Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000 // J. Am. Med. Assoc. — 2003. — Vol. 290, № 2. — P. 199–206.
3. Lloyd-Jones D.M., Evans J.C., Larson M.G., O’Donnell C.J., Roccella E.J., Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community // Hypertension. — 2000. — Vol. 36, № 4. — P. 594–599.
4. Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of hypertension — United States,1999–2002 and 2005–2008 // MMWR Morb. Mortal. Weekly Rep. — 2011. — Vol. 60, № 4. — P. 103–108.
5. Laragh J.H., Baer L., Brunner H.R., Buhler F.R., Sealey J.E., Vaughan E.D. Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease // Am. J. Med. — 1972. — Vol. 52, № 5. — P. 633–652.
6. Laragh J.H. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone proiles // Am. J. Med. — 1973. — Vol. 55, № 3. — P. 261–274.
7. Laragh J. Laragh’s lessons in pathophysiology and clinical pearls for treating hypertension // Am. J. Hypertens. — 2001. — Vol. 14, № 12. — P. 733–742.
8. Laragh J.H. Laragh’s lessons in renin system pathophysiology for treating hypertension and its fatal cardiovascular consequences. — Elsevier Science: New York, 2002. — 174 p.
9. Laragh J.H., Sealey J.E. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long- term blood pressure // Am. J. Hypertens. — 2011. — Vol. 24, № 11. — P. 1164–1180.
10. Blumenfeld J.D., Laragh J.H. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension // Am. J. Hypertens. — 1998. — Vol. 11, № 7. — P. 894–896.
11. Yokoyama S., Kaburagi T. Clinical effects of intravenous nifedipine on renal function // J. Cardiovasc. Pharmacol. — 1983. — Vol. 5, № 1. — P. 67–71.
12. Krusell L.R., Jespersen L.T., Christensen C.K., Thomsen K., Pedersen O.L. Acute natriuresis induced by inhibition of proximal tubular reabsorption of sodium and water in hypertensives following acute calcium entry blockade with nifedipine // J. Cardiovasc. Pharmacol. — 1987. — Vol. 10, Suppl. 10. — P. S162–S163.
13. Furberg C.D. Treatment of hypertension: a failing report card // Am. J. Hypertens. — 2009. — Vol. 22, № 1. — P. 1–2.
14. Laragh J.H., Sealey J.E. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT // Am. J. Hypertens. — 2003. — Vol. 16, № 5, Pt. 1. — P. 407–415.
15. Obarzanek E., Proschan M.A., Vollmer W.M. et al. Indi-vidual blood pressure responses to changes in salt intake. Results from the DASH-Sodium Trial // Hypertension. — 2003. — Vol. 42, № 4. — P. 459–467.
16. Sealey J.E., Laragh J.H. Aliskiren, the irst renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness // Am. J. Hypertens. — 2007. — Vol. 20, № 5. — P. 587–597.
17. Sealey J.E., Parra D., Rosenstein R., Laragh J.H. «Effective» plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers // Hypertension. — 2010. — Vol. 55, № 3. — P. e16.
18. Hasler C., Nussberger J., Maillard M., Forclaz A., Brunner H.R., Burnier M. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor // Clin. Pharmacol. Ther. — 2005. — Vol. 78, № 5. — P. 501–507.
19. Sim J.J., Bhandari S.K., Shi J., Kalantar-Zadeh K., Rasgon S.A., Sealey J.E. et al. Use of antihypertensive medications in a large healthcare system: relationship to plasma renin activity (PRA) levels // Am. J. Hypertens. — 2012. — Vol. 25, № 3. — P. 379–388.
20. Blumenfeld J.D., Sealey J.E., Mann S.J., Bragat A., Marion R., Pecker M.S. et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects // Am. J. Hypertens. — 1999. — Vol. 12, № 5. — P. 451–459.
21. Weber M.A., Case D.B., Baer L., Sealey J.E., Drayer J.I., Lopez-Overjero J.A., Laragh J.H. Renin and aldosterone suppression in the antihypertensive action of clonidine // Am. J. Cardiol. — 1976. — Vol. 38, № 6. — P. 825–830.
22. Safar M.E., Weiss Y.A., Corvol P.L., Menard J.E., London G.M., Milliez P.L. Anti-hypertensive adrenergic-blocking agents: effects on sodium balance, the renin-angiotensin system and haemodynamics // Clin. Sci. Mol. Med. Suppl. — 1975. —Vol. 2. — P. 93s–95s.
23. Vaughan E.D., Laragh J.H., Gavras I., Buhler F.R., Gavras H., Brunner H.R., Baer L. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone // Am. J. Cardiol. — 1973. — Vol. 32, № 4. — P. 523–532.
24. Weber M.A., Lopez-Ovejero J.A., Drayer J.I., Case D.B., Laragh J.H. Renin reactivity as a determinant of responsiveness to antihypertensive treatment // Arch. Intern. Med. — 1977. — Vol. 137, № 3. — P. 284–289.
25. Case D.B., Atlas S.A., Laragh J.H., Sealey J.E., Sullivan P.A., McKinstry D.N. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients // Prog. Cardiovasc. Dis. — 1978. — Vol. 21, № 3. — P. 195–206.
26. Muller F.B., Sealey J.E., Case D.B., Atlas S.A., Pickering T.G., Pecker M.S. et al. The captopril test for identifying renovascular disease in hypertensive patients // Am. J. Med. — 1986. — Vol. 80, № 4. — P. 633–644.
27. Alderman M.H., Cohen H.W., Sealey J.E., Laragh J.H. Pressor responses to antihypertensive drug types // Am. J. Hypertens. — 2010. — Vol. 23, № 9. — P. 1031–1037.
28. Furberg C.D. Renin-guided treatment of hypertension: time for action // Am. J. Hypertens. — 2010. — Vol. 23, № 9. — P. 929–930.
29. Goldblatt H., Lynch J., Hanzal R.F., Summerville W.W. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renalischemia // J. Exp. Med. — 1934. — Vol. 59, № 3. — P. 347–379.
30. Laragh J.H., Sealey J.E., Sommers S.C. Patterns of adrenal secretion and urinary excretion of aldosterone and plasma renin activity in normal and hypertensive subjects // Circ. Res. — 1966. — Vol. 18, Suppl. I. — P. 158–174.
31. Brunner H.R., Kirshman J.D., Sealey J.E., Laragh J.H. Hypertension of renal origin: evidence for two different mechanisms // Science. — 1971. — Vol. 174, № 4016. — P. 1344–1346.
32. Gavras H., Brunner H.B., Vaughan E.D., Laragh J.H. Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats // Science. — 1973. — Vol. 180, № 4093. — P. 1369–1371.
33. Gavras H., Ribeiro A.B., Gavras I., Brunner H.R. Reciprocal relation between renin dependency and sodium dependency in essential hypertension // N. Engl. J. Med. — 1976. — Vol. 295, № 23. — P. 1278–1283.
34. Assaykeen T.A., Clayton P.L., Goldien A., Ganong W.F. The effect of alpha- and beta-adrenergic blocking agents on the renin response to hypoglycemia and epinephrine in dogs // Endocrinology. — 1970. — Vol. 87, № 6. — P. 1318–1322.
35. Michelakis A.M., McAllister R.G. The effect of chronic adrenergic receptor blockade on plasma renin activity in man // J. Clin. Endocrinol. Metab. — 1972. — Vol. 34, № 2. — P. 386–394.
36. Buhler F.R., Laragh J.H., Baer L., Vaughan E.D., Brunner H.R. Propranolol inhibition of renin secretion. A speciic approach to diagnosis and treatment of renin-dependent hypertensive diseases // N. Engl. J. Med. — 1972. — Vol. 287, № 24. — P. 1209–1214.
37. Buhler F.R., Laragh J.H., Vaughan E.D., Brunner H.R., Gavras H., Baer L. Antihypertensive action of propranolol. Speciic antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension // Am. J. Cardiol. — 1973. — Vol. 32, № 4. — P. 511–522.
38. Gavras H., Brunner H.R., Laragh J.H., Sealey J.E., Gavras I., Vukovich R.A. An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients // N. Engl. J. Med. — 1974. — Vol. 291, № 16. — P. 817–821.
39. Case D.B., Wallace J.M., Keim H.J., Weber M.A., Sealey J.E., Laragh J.H. Possible role of renin in hypertension as suggested by renin-sodium proiling and inhibition of converting enzyme // N. Engl. J. Med. — 1977. — Vol. 296, № 12. — P. 641–646.
40. Case D.B., Atlas S.A., Laragh J.H., Sealey J.E., Sullivan P.A., McKinstry D.N. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients // Prog. Cardiovasc. Dis. — 1978. — Vol. 21, № 3. — P. 195–206.
41. Case D.B., Wallace J.M., Keim H.J., Sealey J.E., Laragh J.H. Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients // Am. J. Med. — 1976. — Vol. 60, № 6. — P. 825–836.
42. Timmermans P.B., Carini D.J., Chiu A.T., Duncia J.V., Price W.A., Wells G.J. et al. The discovery of a new class of highly speciic nonpeptide angiotensin II receptor antagonists // Am. J. Hypertens. — 1991. — Vol. 4, № 4, Pt. 2. — P. 275S–281S.
43. Sealey J.E., Laragh J.H. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insuficiently or reactively rises // Am. J. Hypertens. — 2009. —Vol. 22, № 1. — P. 112–121.
44. Vaughan E.D., Laragh J.H., Gavras I., Buhler F.R., Gavras H., Brunner H.R., Baer L. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone // Am. J. Cardiol. — 1973. — Vol. 32, № 4. —P. 523–532.
45. Laragh J.H. Modern system for treating high blood pressure based on renin proiling and vasoconstriction-volume analysis: a primary role for beta blocking drugs such as propranolol // Am. J. Med. — 1976. — Vol. 61, № 5. — P. 797–810.
46. Brunner H.R., Laragh J.H., Baer L., Newton M.A., Goodwin F.T., Krakoff L.R. et al. Essential hypertension: renin and aldosterone, heart attack and stroke // N. Engl. J. Med. — 1972. — Vol. 286, № 9. — P. 441–449.
47. Alderman M.H., Madhavan S., Ooi W.L., Cohen H., Sealey J.E., Laragh J.H. Association of the renin-sodium proile with the risk of myocardial infarction in patients with hypertension // N. Engl. J. Med. — 1991. — Vol. 324, № 16. — P. 1098–1104.
48. Blumenfeld J.D., Sealey J.E., Alderman M.H., Cohen H., Lappin R., Catanzaro D.F., Laragh J.H. Plasma renin activity in the emergency department and its independent association with acute myocardial infarction // Am. J. Hypertens. — 2000. — Vol. 13, № 8. — P. 855–863.
49. Gonzalez M.C., Cohen H.W., Sealey J.E., Laragh J.H.,
50. Alderman M.A. Enduring direct association of baseline plasma
51. renin activity with all-cause and cardiovascular mortality in hypertensive patients // Am. J. Hypertens. — 2011. — Vol. 24, № 11. — P. 1181–1186.
52. Muller F.B., Sealey J.E., Case D.B., Atlas S.A., Pickering T.G., Pecker M.S. et al. The captopril test for identifying renovascular disease in hypertensive patients // Am. J. Med. — 1986. — Vol. 80, № 4. — P. 633–644.
53. Furberg C.D. Renin test-guided drug treatment of hypertension: the need for clinical trials // Am. J. Hypertens. — 2011. — Vol. 24, № 11. — P. 1158–1163.
54. Blumenfeld J.D., Laragh J.H. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension // Am. J. Hypertens. — 1998. — Vol. 11, № 7. — P. 894–896.
55. Egan B.M., Basile J.N., Rehman S.U. et al. Plasma renin test- guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial // Am. J. Hypertens. — 2009. — Vol. 22, № 7. — P. 792–801.
56. Sealey J.E. Plasma renin activity and plasma prorenin assays // Clin. Chem. — 1991. — Vol. 37, № 10, Pt. 2. — P. 1811–1819.
57. Jones M.R., Sealey J.E., Laragh J.H. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake // Am. J. Hypertens. — 2007. — Vol. 20, № 8. — P. 907–916.
58. Sealey J.E., Gerten-Banes J., Laragh J.H. The renin system: variations in man measured by radioimmunoassay or bioassay // Kidney Int. — 1972. — Vol. 1, № 4. — P. 240–253.
59. Sealey J.E., Laragh J.H. Radioimmunoassay of plasma renin activity // Semin. Nucl. Med. — 1975. — Vol. 5, № 2. — P. 189–202.
60. Egan B.M., Basile J.N., Rehman S.U., Davis P.B., Grob C.H., Riehle J.F. et al. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial // Am. J. Hypertens. — 2009. — Vol. 22, № 7. — P. 792–801.
61. Turner S.T., Schwartz G.L., Chapman A.B. et al. Plasma renin activity predicts blood pressure responses to ?-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension // Am. J. Hypertens. — 2010. — Vol. 23, № 9. — P. 1014–1022.
62. Vaclavik J., Sedlak R., Plachy M. et al. Addition of spironolactone in patients with resistant arterial hypertension (AS-PIRANT): a randomized, double-blind, placebo-controlled trial // Hypertension. — 2011. — Vol. 57, № 6. — P. 1069–1075.
63. Schwartz G.L., Bailey K., Chapman A.B., Boerwinkle E., Turner S.T. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension // Am. J. Hypertens. — 2013. — Vol. 26, № 8. — P. 957–964.
64. Bell A.J., Lindner A. Effects of verapamil and nifedipine on renal function and hemodynamics in the dog // Ren. Physiol. — 1984. — Vol. 7, № 6. — P. 329–343.
Рецензия
Для цитирования:
Котовская Ю.В., Кравцова О.А., Павлова Е.А. ОПРЕДЕЛЕНИЕ АКТИВНОСТИ РЕНИНА ПЛАЗМЫ КАК СТРАТЕГИЯ ВЫБОРА И ИЗМЕНЕНИЯ АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ. Артериальная гипертензия. 2013;19(5):380-388. https://doi.org/10.18705/1607-419X-2013-19-5-380-388
For citation:
Kotovskaya Yu.V., Kravtsova O.A., Pavlova E.A. PLASMA RENIN ASSESSMENT AS THE STRATEGY OF HYPERTENSION MANAGEMENT. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2013;19(5):380-388. (In Russ.) https://doi.org/10.18705/1607-419X-2013-19-5-380-388
Просмотров:
4725
Послать статью по эл. почте 